These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 35772417)

  • 21. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
    Sullivan AK; Saunders J; Desai M; Cartier A; Mitchell HD; Jaffer S; Ogaz D; Chiavenna C; Charlett A; Diamente V; Golombek R; Manavi K; Priestley C; Waters LJ; Milinkovic A; McOwan A; Estcourt C; Sabin CA; Rodger A; Gold D; Gazzard BG; McCormack S; Gill ON;
    Lancet HIV; 2023 Dec; 10(12):e790-e806. PubMed ID: 38040478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
    Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
    Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study.
    Liegeon G; Assoumou L; Ghosn J; El Mouhebb M; Palich R; Palacios C; Slama L; Surgers L; Genin M; Beniguel L; Goldwirt L; Duvivier C; Rojas Castro D; Costagliola D; Molina JM
    J Antimicrob Chemother; 2022 Nov; 77(12):3427-3435. PubMed ID: 36205009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
    J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
    Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
    Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
    Siguier M; Mera R; Pialoux G; Ohayon M; Cotte L; Valin N; Ghosn J; Cua E; Pintado C; Chas J; Barriere G; Durand F; Molina JM
    J Antimicrob Chemother; 2019 Sep; 74(9):2752-2758. PubMed ID: 31219561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
    Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-exposure prophylaxis in real life: experience from a prospective, observational and demonstration project among men who have sex with men in Benin, West Africa.
    Diabaté S; Béhanzin L; Guédou FA; Goma-Matsétsé E; Olodo M; Aza-Gnandji M; Dossouvo A; Akpaka A; Chagas E; Gangbo F; Zannou DM; Alary M
    J Int AIDS Soc; 2023 Jun; 26(6):e26130. PubMed ID: 37306106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study.
    Wu D; Tao H; Dai J; Liang H; Huang A; Zhong X
    Int J Environ Res Public Health; 2019 Dec; 16(24):. PubMed ID: 31818006
    [No Abstract]   [Full Text] [Related]  

  • 34. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
    McCormack S; Dunn DT; Desai M; Dolling DI; Gafos M; Gilson R; Sullivan AK; Clarke A; Reeves I; Schembri G; Mackie N; Bowman C; Lacey CJ; Apea V; Brady M; Fox J; Taylor S; Antonucci S; Khoo SH; Rooney J; Nardone A; Fisher M; McOwan A; Phillips AN; Johnson AM; Gazzard B; Gill ON
    Lancet; 2016 Jan; 387(10013):53-60. PubMed ID: 26364263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study.
    Zhang J; Xu JJ; Wang HY; Huang XJ; Chen YK; Wang H; Chu ZX; Hu QH; He XQ; Li Y; Zhang LK; Hu ZL; Bao RT; Li SC; Li H; Ding HB; Jiang YJ; Geng WQ; Sylvia S; Shang H;
    J Int AIDS Soc; 2021 Feb; 24(2):e25667. PubMed ID: 33586841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence.
    Vuylsteke B; Reyniers T; De Baetselier I; Nöstlinger C; Crucitti T; Buyze J; Kenyon C; Wouters K; Laga M
    J Int AIDS Soc; 2019 Oct; 22(10):e25407. PubMed ID: 31663257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
    Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
    Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.